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ABSTRACT
Background Early access to diagnosis is crucial 
for effective management of any disease including 
tuberculosis (TB). We investigated the barriers and 
opportunities to maximise uptake and utilisation of 
molecular diagnostics in routine healthcare settings.
Methods Using the implementation of WHO approved TB 
diagnostics, Xpert Mycobacterium tuberculosis/rifampicin 
(MTB/RIF) and Line Probe Assay (LPA) as a benchmark, we 
evaluated the barriers and how they could be unlocked to 
maximise uptake and utilisation of molecular diagnostics.
Results Health officers representing 190 districts/
counties participated in the survey across Kenya, Tanzania 
and Uganda. The survey findings were corroborated by 
145 healthcare facility (HCF) audits and 11 policy- maker 
engagement workshops. Xpert MTB/RIF coverage was 
66%, falling behind microscopy and clinical diagnosis by 
33% and 1%, respectively. Stratified by HCF type, Xpert 
MTB/RIF implementation was 56%, 96% and 95% at 
district, regional and national referral hospital levels. LPA 
coverage was 4%, 3% below culture across the three 
countries. Out of 111 HCFs with Xpert MTB/RIF, 37 (33%) 
used it to full capacity, performing ≥8 tests per day of 
which 51% of these were level five (zonal consultant 
and national referral) HCFs. Likewise, 75% of LPA was 
available at level five HCFs. Underutilisation of Xpert 
MTB/RIF and LPA was mainly attributed to inadequate—
utilities, 26% and human resource, 22%. Underfinancing 
was the main reason underlying failure to acquire 
molecular diagnostics. Second to underfinancing was lack 
of awareness with 33% healthcare administrators and 
49% practitioners were unaware of LPA as TB diagnostic. 
Creation of a national health tax and decentralising its 
management was proposed by policy- makers as a booster 
of domestic financing needed to increase access to 
diagnostics.
Conclusion Our findings suggest higher uptake and 
utilisation of molecular diagnostics at tertiary level HCFs 
contrary to the WHO recommendation. Country- led 
solutions are crucial for unlocking barriers to increase 
access to diagnostics.
INTRODUCTION
The COVID-19 pandemic led to worldwide 
shutdown and saw unprecedented uptake 
and utilisation of molecular diagnostics with 
over 500 million tests conducted in a period 
of 9 months ( statista. com, 9 October 2020). 
The rapidly evolving COVID-19 is responsible 
36.99 million cases and 1.1 million deaths 
(WHO COVID-19 Dashboard, 11 October 
2020).1 The health systems have been 
shaken but most importantly the pandemic 
has raised public consciousness of the value 
Key questions
What is already known?
 ► Diagnostics are critical for effective management 
of disease. This is more so for tuberculosis (TB), a 
treatable disease but millions go undetected and un-
treated every year.
What are the new findings?
 ► Contrary to WHO recommendation, implementation 
of Xpert MTB/RIF and Line Probe Assay is higher 
at tertiary, that is, regional and national healthcare 
levels, respectively. Despite the usual culprit (under-
financing), our study reveals that unawareness by 
healthcare administrators, practitioners and service 
users is a strong limiting factor to uptake and utilisa-
tion of diagnostics.
What do the new findings imply?
 ► Low access to diagnosis by people living in areas 
served by primary healthcare facilities, which per-
haps explain the 3 million TB cases that go undetect-
ed every year. Bottom- up country- led solutions are 
critical for increasing access to diagnostics.
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of diagnostics and interdisciplinary approaches in the 
control of diseases. In contrast, tuberculosis (TB) has 
been a pandemic for time immemorial and a global 
public health emergency for over 20 years.2 3 A quarter 
(1.7 billion) of the world population have TB infection 
and in 2018, 10 million developed active disease resulting 
in 1.5 million deaths.4–6 Of the 10 million notified cases, 
55% were bacteriologically confirmed and a small 
proportion of these were tested using rapid molecular 
tests.5 The rate of TB testing does not match incidence 
of TB disease and, consequently, an estimated 3 million 
cases go undetected every year.7
WHO approved routine use of TB molecular tests 
more than 10 years ago, starting with the Line Probe 
Assay (LPA) in 2008 and Xpert Mycobacterium tubercu-
losis/rifampicin (MTB/RIF) in 2010.8 9 The latter detects 
both TB and resistance to rifampicin in 2 hours and is 
the widely used molecular test for TB. By 2016, only 
16 million Xpert MTB/RIF tests had been performed, 
translating into 3.2 million tests per year.10 While there 
is been steady progress in the uptake and use of Xpert 
MTB/RIF, the impact of using the same GeneXpert 
platform for testing HIV viral load and more recently 
COVID-19 on TB diagnosis is yet to be unravelled.11 12 
There is sharp contrast in the rate of uptake of COVID-19 
molecular tests compared with TB and could a leaf be 
borrowed from either disease on how to accelerate and 
maximise translation of health research innovations into 
policy and practice?
The impact of effective diagnostic testing is not only 
the ability to detect disease but also contribution to 
favourable clinical outcomes for patients. This is more 
likely to be achieved in a health system landscape that 
employs holistic approach to patient care as enshrined 
in the ‘WHO End TB strategy’: integrated patient- 
centred care and prevention to foster early diagnosis, 
universal drug- susceptibility testing, systematic screening 
of contacts and high- risk group, treatment of all people. 
Good governance and leadership to ensure equal access 
to healthcare, safe medicines and social protection to 
minimise impact of economic status on quality of care 
received. Last but not least, intensifying research and 
innovation to ensure discovery, development, optimisa-
tion and rapid uptake of new tools, interventions and 
strategies coupled with monitoring and evaluation to 
ascertain impact.13–15
Low- income and middle- income countries (LMICs) 
account for over 50% of the global TB burden.5 The scar-
city of resources complicates the development of strong 
health systems and more so when the COVID-19 effect 
which is estimated to have reduced TB care delivery by 
20% is taken into account.12 Models to ensure access of 
service by those that need them the most have been devel-
oped.16–18 For instance, Kenya used patient pathway anal-
ysis (PPA) model to assess the delivery of TB diagnostic 
and treatment and found more than 50% of the low- level 
healthcare facilities (HCFs) where majority people seek 
care did not have diagnostic services.19 Confronted by 
this finding, Kenya committed to redesigning the provi-
sion of TB services to ensure they are in places where they 
are most needed rather than where it is operationally 
convenient, such as tertiary level HCFs in urban settings. 
Kenya adopted this approach around the same time as 
our study, it will be interesting to assess the impact made 
on uptake and utilisation of molecular diagnostics for TB 
in the country.
Using the implementation of TB diagnostics as a 
model, we sought to understand the ways to maximise 
uptake and utilisation of diagnostic technologies that 
have regulatory approval and are supported by WHO 
and other expert opinion within the health systems. Our 
findings show higher rate of uptake and utilisation of TB 
diagnostics at tertiary level HCFs. In contrast to the WHO 
endorsement, LPA is mainly implemented at zonal—
national level instead of regional HCF while Xpert MTB/
RIF was more utilised at regional, zonal—national level 
HCFs instead of the recommended district level hospitals. 
These data point to hub- centralised model of implemen-
tation in order to maximise both uptake and utilisation 
of the diagnostics platforms. Resolving the health system, 
socioeconomic and cultural bottlenecks is pivotal for the 
effective implementation of either the PPA or centralised 
model of diagnostic services.
Recommended solutions
 ► Improving human resource capacity and efficiency: Considering the 
paucity of finances to hire and retain skilled workforce in resource 
limited settings, efficiency in provision of molecular diagnostic ser-
vices could be improved by operating a hub system. This allows 
consolidation of skilled human resources at specific HCFs across 
the country. Secondly, providing flexible working conditions will en-
able staff attend training to upgrade their skills as well as attracting 
skilled part- time workers.
 ► Increasing uptake of molecular diagnostics at HCF levels 1, 2, 3 
and 4: some level 3 and 4 HCF can be converted into molecular 
diagnostics hubs serving a network of levels 1 and 2 HCFs. Each 
district (for Uganda and Tanzania) or subcounty (for Kenya) could 
have one hub receiving and processing specimens from HCFs in 
the area. Investing in laboratory information systems and electronic 
health records would ensure results feedback to respective clinics 
as soon as sample processing is finished.
 ► Stability of utilities: Water and electricity are crucial for running both 
clinical and laboratory procedures. Investing in extension of piped 
water to HCFs and solar power will go a long way in ensuring con-
sistent health service delivery.
 ► Streamlining procurement services: Consultative approach be-
tween national- local healthcare administrators, service users and 
private sector will help identify efficient ways to procure supplies 
and ensure timely healthcare service delivery.
 ► Increasing domestic financing of healthcare services: Based on 
5- year WHO reporting prior to the study, over 50% of funding for 
TB services came from donor funds. Policy- makers’ suggestion of 
creating a health fund supported by local tax revenues is practical 
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METHODS
This was a mixed- methods study employing both quan-
titative and qualitative approaches including surveys of 
district/county health officers, HCF audits, in- depth one- 
on- one interviews, focus group discussions (FGDs) and 
dialogues with policy- makers. The study was conducted 
between September 2016 to December 2017 in Uganda, 
Kenya and Tanzania. At the time of the study, only Kenya 
was defined as a middle income country, and it has now 
been joined by Tanzania in this classification.20
Consortium
The study was conducted under the TWENDE consortium 
and comprised seven institutions: Makerere University 
and CPAR Uganda Ltd Uganda, Kenya Medical Research 
Institute (KEMRI) Kenya, Kilimanjaro Clinical Research 
Institute (KCRI) and National Institute for Medical 
Research (NIMR)—Mbeya Medical Research Centre 
Tanzania while the East African Community was repre-
sented by the East African Health Research Commission, 
and University of St Andrews, UK. TWENDE, which is 
Swahili word means ‘let’s go!’ is abbreviated from Tuber-
culosis: Working to Empower the Nations’ Diagnostic 
Effort.
Geography and participants
Areas of coverage were selected based on the TB diag-
nostics, LPA and Xpert MTB/RIF (GeneXpert) approved 
areas of implementation. According to the WHO, LPA 
and Xpert MTB/RIF are recommended for implemen-
tation at regional and district level hospitals respectively. 
In Uganda, regions were based on areas represented by 
a regional hospital while districts were taken as they are 
currently structured as administration units. In Tanzania, 
regions and districts are clearly demarcated admin-
istrative units and so were covered as such. For Kenya, 
regional units were counties while the subcounties were 
equivalent to districts in Uganda and Tanzania. Study 
districts, regions or counties were purposively selected 
to be representative of all geographical regions of the 
country.
Participants were healthcare administrators such as 
regional/county and district health (medical) officers, 
HCF managers and healthcare professionals of partic-
ipating HCFs. Apart from managers and practitioners, 
patients, TB survivors, community health volunteers, 
opinions leaders among the HCF users, local council 
leaders and national policy- makers in ministry of Health 
and parliament were engaged. Participants were selected 
based on their role either as healthcare leader/manager 
or practitioner and/or by their status as patients with 
TB, caregivers or survivors. The managers and practi-
tioners represented opinion from health system service 
delivery perspective while the patients, caregivers and 
survivors shared their lived experiences in accessing 
diagnosis and treatment as well as living with TB in a 
community.
Survey
An online survey was constructed using the University 
of St Andrews licensed Qualtrics survey tool (https:// 
standrews. eu. qualtrics. com). The tool was commissioned 
by the University of St Andrews teaching and research 
ethics and complies with the European Union General 
Data Protection regulation EU2016/679 and the local 
country Ethics committees. The purpose of the survey 
was to obtain an overview of the challenges and opportu-
nities confronting TB diagnostics and treatment services 
from the perspective of regional/county and district/
sub- county health or medical officers (see online supple-
mental file 1). It sought to know what facility and/or 
service is available and if not available, what could be the 
underlying reasons. The survey was made compatible 
with all computer systems, Windows and macOS, and 
both Android and Apple smart phones. The opening 
page of the questionnaire had participant information 
and solicitation for consent to participate in the study.
HCF audits
The rationale of the audit was to verify the responses 
given by survey participants and gain more insight 
into the implementation of TB diagnostics on ground. 
The audit tool was developed and teams of researchers 
in each country were trained to administer the tool at 
selected HCFs. The respondents at the HCFs were the 
healthcare and laboratory managers at regional/county 
and district/subcounty hospitals. The audit ascertained 
whether the facilities and services reported by the survey 
participants were indeed available and being used. In 
addition to interviews with healthcare practitioners, the 
auditors inspected the facilities to verify answers given. 
See online supplemental file 2.
Policy dialogues
Workshops were organised targeting policy- makers and 
implementers to discuss views from the general commu-
nity and construct actionable policy briefs for the national 
policies to implement. Participants in these were work-
shops were parliamentarians, technocrats from Minis-
tries of Health, leaders from regional/county adminis-
trative units, and representatives of other disease control 
agencies.
‘Chatham House Rules’ were used during the FGDs 
and policy dialogues to promote open expression of views 
and opinions without fear of being vilified. The Chatham 
House rule states: ‘When a meeting, or part thereof, is 
held under the Chatham House Rule, participants are 
free to use the information received, but neither the 
identity nor the affiliation of the speaker(s), nor that of 
any other participant, may be revealed’. Coverage was 
defined as presence or absence of the diagnostic plat-
form at HCFs as per the WHO recommendation. Utili-
sation was defined as the frequency of using a particular 
diagnostic platform as per the WHO recommendation. 
Presence or absence of referral network was acknowl-
edged as an enabler but not basis of the definition.
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Data analysis
Quantitative data were analysed using Microsoft Excel 
2016 and GraphPad Prism V.6. Percentage diagnostic 
coverage and utilisation was calculated per type of HCF 
and all HCFs combined. Analysis of variance (ANOVA) 
multiple comparisons test was used to assess the perfor-
mance difference between HCFs. Significance was consid-
ered at p<0.05% and 95% CI.
Patient and public involvement statement
This study emerged as result of the challenges that had 
been experienced during implementation evaluation of 
new molecular diagnostic for TB in Malawi, Mozambique 
and Tanzania. Utilities like electricity and water were 
unstable and complex procurement landscape resulting 
in lost laboratory experiments and laboratory supplies 
at customs respectively. In response the researchers 
engaged all stakeholders to gain holistic understanding 
of the barriers and how they can be overcome. Partici-
pants who contributed to the discussion were Survivors of 
TB, carers, community opinion leaders, practitioners and 
policy- makers. Open FGDs were held in each region and/
or county for Uganda, Tanzania and Kenya. Regional 
and national dialogues with policy- makers were held in 
each country and policy brief submitted to respective 
ministries of health and parliaments. Once published, 
the paper will be translated into lay English and local 
languages and publish in newspapers for access to the 
general public in the study countries.
RESULTS
Participants and study area
A total of 217 survey responses received from district 
or county healthcare officers across the three coun-
tries. After removal of duplicate/multiple responses per 
district or county, 190 entries representing 27 (14%), 66 
(35%) and 97 (51%) from Kenyan counties, Tanzanian 
and Ugandan districts, respectively, were considered for 
analysis. The Kenyan county was considered equivalent 
of Ugandan or Tanzanian region. The 27 Kenyan coun-
ties varied in size, median (range) 5 (2–17) subcounties 
(districts), together constituting an area of 159 subcoun-
ties and 57% of Kenyan counties. All the 14 Ugandan 
and 26 Tanzania mainland regions were represented in 
the survey. Time spent in the post by respondents ranged 
from less than 1 year to 16 years: 14 (7%) less than 
1 year, 35 (16%) 1–2 years, 53 (24%) 3–4 years, 41 (19%) 
5–6 years, 29 (13%) 7–8 years, 16 (7%) 9–10 years and 
29 (13%) over 10 years. Most health officers performed 
a combination of more than three roles. The most and 
least frequently played roles were supervision of health-
care provision (97%) and paying healthcare workers’ 
salaries (9%). There was no unique association between 
particular roles and degree of implementation of diag-
nostic tools (table 1).
The on- site audits HCFs recapitulated the survey results. 
A total of 145 HCFs were audited, 48 (33%) each for Kenya 
and Uganda and 49 (34%) Tanzania. This represents 
42% (112), 29% (169) and 44% (47) of the districts and 
counties in Uganda, Tanzania and Kenya, respectively, at 
the time of audit. In all the countries, government was 
the main TB clinical service provider, owning over 80% 
of the HCFs. Level 5 hospitals (national, consultant level, 
regional referral) were 42, level 4 (regional hospitals) 
34, level 3 (district hospitals) 57, level 2 (health centre 
IV) 6 and level 1 (dispensary, health centre 1–3) 6. The 
majority, 86 of the TB laboratories were able to deliver 
biosafety level II (BSL II) followed by BSL I, 23 and BSL 
III, 6 and 4 general laboratories.
Coverage of diagnostics
At the time of the survey, smear microscopy was the most 
available diagnostic tool, 97% (185/190) followed by 
clinical diagnosis, 67% (128/190) and Xpert MTB RIF, 
66% (125/190) of the districts/counties surveyed. TB 
culture and LPA were the least available, 7% (13/190) 
and 4% (8/190). Most of the districts, 89% (169) 
reported microscopy in combination with other diagnos-
tics leaving only 11% (21) which had only microscopy for 
diagnosis. At country level, Xpert MTB/RIF test coverage 
was 74% (72/97) and 39% (26/66) districts in Uganda 
and Tanzania respectively and 42% (67/159) subcoun-
ties in Kenya (figure 1).
The number of Xpert MTB/RIF test machines (GeneX-
pert) was not consistent with the number of subcoun-
ties (districts) per county in Kenya. Some counties had 
less than the number of the subcounties and vice versa 
(online supplemental figure 1).
The coverage results were replicated in the on- site 
audit of 145 HCFs: smear microscopy availability 142 
Table 1 Roles performed by district and/or county health 
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(98%), Xpert MTB/RIF 111 (76%), Culture 5 (4%) and 
LPA 4 (3%). Number of available of Xpert MTB/RIF 
instruments increased with increasing level of HCF. Out 
of the 111 HCFs possessing Xpert MTB/RIF, 1 (0.9%), 
5 (5%), 32 (29%), 33 (30%) and 40 (36%) were level 1, 
2, 3, 4 and 5 HCFs, respectively. Availability within the 
HCF type, level 4 and 5 had the highest, 97% and 95% 
coverage of Xpert MTB/RIF instruments followed by 
level 2, 83%, level 3 (56%) and level 1, 17% (figure 2).
Out the four HCFs in possession of LPA, three were 
L5 (one national, one zonal referral and one consultant 
hospital) and only one was L4 (regional). This implies 
out of 34 audited regional hospitals, only one had LPA 
service as per WHO recommendation. All the five HCFs 
with culture were L5 (two national referral, two consul-
tant and one zonal referral hospitals).
Utilisation of diagnostics
Smear microscopy
Taken together, number of smears performed per 
month by HCFs with microscopy services (142) were 
median (range) 56 (0.8–460). The number of smears 
performed increased with the HCF level, 26 (17–75), 
18 (1.3–60), 46 (0.8–460), 48 (1.3–400) and 89 (5–311) 
at HCF level 1, 2, 3, 4 and 5, respectively. Only HCF 
level 5 performed above median number of smears 
per month. Of the 142 HCFs that performed micros-
copy, 96% (137) used it for diagnosis and treatment 
follow- up. The most frequent use of smear micros-
copy was treatment follow- up, 50% (68) followed 
by combination of primary diagnosis and treatment 
follow- up, 40% (55). The proportion of using micros-
copy as a primary diagnostic tool was high, 33% in 
level one (L1) HCFs vs 10% in L5 HCFs, and 67% vs 
26% for using microscopy for both primary diagnosis 
and treatment follow- up (table 2).
Xpert MTB/RIF
Like coverage, utilisation of Xpert MTB/RIF 
increased with level of HCF, median (IQR) 0 (0–4), 
90 (33–390), 120 (55–170), 200 (110–240), 228 (110–
320) tests per month at level 1, 2, 3, 4 and 5 HCF, 
respectively, linear regression p=0.002. The ordinary 
one- way ANOVA multiple comparisons test showed 
significant difference of tests performed at different 
HCFs, F=5.4, p=0.0005. However, the difference was 
driven by tests at level 4 and 5 which were significantly 
higher than level 1 and both level 1 and 3 HCFs, 
respectively. Out of the 111 sites with Xpert MTB/
RIF test instruments, only 37 (33%) used the instru-
ments to full capacity, performing at least 8 tests per 
day or 240 tests per month. Of the HCFs using Xpert 
MTB/RIF to full capacity, 8% (3), 14% (5), 27% (10) 
and 51% (19) of these HCFs were level 2, 3, 4 and 
5 respectively. None of the level 1 HCFs performed 
Xpert MTB/RIF to capacity (figure 3A,B).
All Xpert MTB/RIF test machines except 2 (1.8%) 
were operated in designated laboratory space and not 
at point- of- care (consultation room) or ward. Most 
HCFs prescribed Xpert MTB/RIF test to all presump-
tive TB cases, 86% (95/111). Where Xpert MTB/RIF 
was not prescribed to all, these groups of cases were 
prioritised, ‘health workers, prisoners, children (0–14 
years), diabetic mothers, HIV positive clients who 
are coughing and on retreatment, contacts of drug- 
resistant TB patients, retreatment cases, treatment 
absconders, relapse cases, retreatment cases, refu-
gees and expecting mothers’. It is important to note 
that by the end of 2019, Kenya, Tanzania and Uganda 
had updated their national TB control guidelines 
recommending Xpert MTB/RIF test to all presump-
tive cases hence more HCFs are currently having the 
Xpert MTB/RIF machines. Xpert MTB/RIF machine 
operational condition and reagent procurement were 
assessed and showed 87% (96/111) of the HCFs had 
Figure 1 The Xpert MTB/RIF coverage in the surveyed 
districts and counties in Uganda, Kenya and Tanzania. The 
highest coverage was 3, 4 and 9 per district or county in 
Uganda, Tanzania and Kenya, respectively. Orange strip 
shading denotes districts or counties surveyed. The size of 
the blue circles denotes the number of the Xpert MTB/RIF 
machines starting from zero or no Xpert MTB/RIF machine 
(smallest blue circle).
Figure 2 Xpert MTB/RIF coverage. (A) Percentage HCFs 
with Xpert MTB/RIF proportional to the total number of HCFs 
in possession of Xpert MTB/RIF (n=111). (B) Xpert MTB/RIF 
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their machines calibrated, 89% (99/111) had stable 
supply of cartridges and 76% (85/111) received the 
cartridges on time. The magnitude of effect by each 
factor varied from HCF- to- HCF with a trend to better 
service at high HCF level (figure 4A–F).
Line Probe Assay
Utilisation of the LPA was quite irregular. Out of the 
four HCFs that had an established LPA service, one 
performed it on request, 64 tests per month, the second 
was twice a month, 24 tests per month and the third 
performed only the day they were trained and since 
then never performed it again. When asked what the 
limiting factor was for not performing LPA again, they 
said, ‘can’t tell, a team came here trained us on LPA 
and left, since then we have never done anything, we 
actually don’t remember what we learned’ Laboratory 
manager at a Regional Hospital. The fourth HCF gave 
no answer on how they used their LPA service. Of the 
four HCFs that had LPA, three (75%) were level 5 and 
one (25%) was level 4.
Underlying limitations for underutilisation or absence of Xpert 
MTB/RIF and LPA services
Some HCFs that had Xpert MTB/RIF attributed 
underutilisation of the service to inadequate human 
resource 22% (24/111), procurement difficulties, 
12% (13/111), poor electricity and water supply, 12% 
(24/111) and 6% (7/111), respectively. The lack of 
Xpert MTB/RIF and LPA services was mainly attrib-
uted to insufficient finance at both district/county 
level (91% and 55%), and at the HCF level (56% and 
21%), respectively. Lack of awareness was a second 
limiting factor to financing revealing 33% and 49% 
of the district/county health officers and healthcare 
practitioners were unaware of the LPA as a diagnostic 
test for TB. Inadequate human resource (24%), lack 
of water (26%) and electricity (26%) were also consid-
ered substantial limitation of implementation of Xpert 
MTB/RIF by practitioners at their HCFs (table 3). A 
total of 6%–9% reported procurement difficulties for 
the two diagnostics, which included reagent stockouts 
and delayed payment of requisitions by the healthcare 
management. ‘Failed procurement is not necessarily 
due to distant (overseas) sources of laboratory supplies, 
in most cases it is due to bureaucracy associated with 
releasing payments, sometimes taking up to 9 months 
to honour requisition or pay an invoice yet we have a 
stock of LPA kits here in Nairobi’, Kenyan Hain Life 
sciences officer.
Inadequate space and test complexity were also iden-
tified as reasons for underutilisation of LPA. In prin-
ciple conducting LPA requires three rooms (pre- PCR, 
PCR and post- PCR) to perform, ‘Very few HCFs in the 
country have such space and person time to perform 
LPA’, Tanzanian senior laboratory scientist.
Culture
Like LPA, culture was a less used diagnostic, 49.6% 
(72/145) of the facilities that we audited. The median 
(range) of culture testing was 1 (0–347) test per month. 
While no culture test was prescribed by HCF level one, 
L2, L3, L4 and L5 prescribed 0.1 (0–0.2), 0.3 (0–36), 0.4 
(0–13) and 10 (0–347) cultures per month, respectively. 
Utilisation improved with HCF level, 0% (0/6), 33% 
(2/6), 40% (23/57), 65% (22/34) and 60% (25/42) 
level 1, 2, 3, 4 and 5 HCFs referring samples for culture. 
Where culture was prescribed, the percentage referral 
for drug sensitivity testing (DST) was 25% (18/72) 
overall and varied across HCF levels, 17% (1/6), 9% 
(5/57), 6% (2/34) and 24% (10/42) at different HCF 
level 2–5, respectively. Time to culture restult was on 
average 2 month for all HCF (figure 5A,B).
Monitoring response to anti-TB therapy
Most of the 145 audited HCFs, 79% (114) used micros-
copy as the only tool for monitoring treatment. This 
included 83% (5/6), 50% (3/6), 82 (47/57), 88% 
Table 2 Utilisation of smear microscopy in audited HCFs
Total L1 (N=6) L2 (N=6) L3 (N=57) L4 (N=34) L5 (N=42)
Primary diagnosis 12 2 (33%) 0% 6 (11%) 0% 4 (10%)
Primary diagnosis of HIV negative cases 2 0 (0%) 0% 2 (4%) 0% 4 (10%)
Primary diagnosis and follow- up 55 3 (67%) 3 (50%) 30 (53%) 7 (21%) 11 (26%)
Follow- up only 68 0 (0%) 3 (50%) 17 (30%) 24 (71%) 24 (57%)
There is high utilisation of microscopy as a primary diagnostic tool in lower level HCFs.
HCFs, healthcare facilities.
Figure 3 Utilisation of Xpert MTB/RIF at different HCF level. 
(A) The number of Xpert MTB/RIF tests conducted per HCF. 
(B) The number of HCFs that performed 240 and above tests 
per month or eight tests per day recommended by WHO 
for full capacity use of Xpert MTB/RIF. In both level, five 
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(30/34) and 69% (29/42) level 1, 2, 3, 4 and 5 HCFs, 
respectively. Other treatment monitoring methods 
used alone were clinical assessment, 2% (3) and Xpert 
MTB/RIF 0.7% (1). One of each level 2, 3 and 5 HCF 
used clinical assessment only while one level 3 HCF 
used Xpert MTB/RIF. Some HCFs used a combination 
of monitoring methods, 3% (4), 4% (5), 4% (5), 1.4% 
(2) and 0.7% (1) for microscopy- clinical assessment, 
microscopy- Xpert MTB/RIF, Xpert MTB/RIF- culture 
and microscopy- Xpert MTB/RIF- chest X- ray, respec-
tively. Combination of microscopy and culture was 
available at two level 4- and three level 5- HCFs only. 
Microscopy- Xpert MTB/RIF was present at one level 1 
and two of each level 3 and 5 HCFs while microscopy- 
Xpert MTB- chest X- ray was available at one level 3 
hospital.
Figure 4 Availability, utilisation, calibration and procurement issues of Xpert MTB/RIF machines. Participants answered yes 
(blue bars) or no (orange bars) to (A) possession of Xpert MTB/RIF test instruments, (B) use of the instrument at point- of- care, 
(C) instrument calibration, (D) prescription of Xpert MTB/RIF test to all presumptive MTB/RIF cases, (E) stable supply of Xpert 
MTB/RIF reagent cartridges and (F) if these cartridges were delivered on time. There was a trend to better performances in all 
parameters at higher healthcare facility levels. HCFs, healthcare facilities.
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Human resource capacity
All HCFs employed certificate and diploma level labora-
tory technicians and medically qualified staff with highest 
proportion (100%) at level 1 and 2 HCFs, respectively. 
There was no bachelor degree qualified laboratory staff 
at level 1 HCFs. The highest proportion of master’s 
degree holders, 38% and clerical staff, 75% was found at 
level 5 HCFs (table 4).
Diagnostic choice making
With a subset of healthcare practitioners (N=22), 
we explored the qualities they would consider when 
choosing a diagnostic test for their practice. A total of 
95% and 82% of the practitioners preferred an expensive 
but more accurate and harder to perform but shorter 
time- to- result diagnostic to a low cost—less accurate and 
longer time- to- result test, respectively (table 5).
Policy-makers’ engagement
Policy- makers were engaged at the initiation—during 
and after completion—of the study. Prestudy engage-
ment gave policy- makers’ perspective on the important 
matters the study should focus on and the channels 
through which findings can be communicated to policy- 
making organs. A total of 11 policy- makers engagement 
workshops were held, three each in Kenya and Tanzania 
and five in Uganda. Dialogues ranged from ways to make 
research to policy making to sustainable uptake and 
utilisation of diagnostic technologies for better health 
outcomes. Policy- makers were keen to be involved in 
research right from inception to the end in order to 
increase translation of outputs into policy and practice. 
Demonstrating research outcomes and impact at county 
(region) level before scale- up to national level was particu-
larly recommended as the best way to increase uptake of 
health research innovations. Creating a national health 
tax and permitting county- regional governments to 
invest a percent of local collected revenues was proposed 
as means of increasing domestic financing and ensure 
sustainable uptake and utilisation of health technologies.
DISCUSSION
Early diagnosis of TB is essential because it shortens time 
to appropriate treatment, prevents severe morbidity and 
mortality.15 21 Using implementation of TB diagnostics as 
a model and benchmarking on the WHO recommenda-
tions, we assessed the barriers and opportunities to over-
come them for maximal uptake and utilisation of diag-
nostic tools into policy and practice in in LMIC setting. 
At the time of research, 2016–2017 the WHO implemen-
tation recommendation was district and regional hospital 
level for Xpert MTB/RIF and LPA, respectively.8 9 Full 
capacity use of Xpert MTB/RIF was set at a minimum 
of eight tests per day while no utilisation limit was set 
for LPA. It is important to note that the actual impact of 
WHO recommendation is realised by customisation into 
country specific policy guidelines.
In the study countries, use of Xpert MTB/RIF and LPA 
was not universal for all presumptive TB. Xpert MTB/RIF 
was recommended for HIV positive cases or those who 
have been in contact with drug resistant case.22–24 LPA 
was modelled along the use of culture recommendation, 
Table 3 The factors underlying lack of Xpert MTB/RIF and LPA services at district/county level and healthcare facility level
District/county level Healthcare facility level








Under financing 91% 55% 56% 21%
Procurement difficulties 9% 7% 6% 8%
Inadequate human resource 1% 3% 24% 0%
No water 1% 0% 26% 0%
No electricity 0% 1% 26% 0%
Biosafety issues 3% 1% 0% 0%
Only available at regional hospital 0% 3% 0% 3%
Not aware of the test 0% 33% 0% 49%
The respondents were district (Uganda and Tanzania) and/or county (Kenya) health officers and healthcare practitioners.
LPA, line probe assay.
Figure 5 Healthcare facilities that referred samples for (A) 
culture (black bars) and drug sensitivity testing (grey bars). 
(B) Time to culture result across different healthcare facilities. 
Level 5 HCFs performed substantially more DST than lower 
level HCFs. The less median time- to- result by level 2 HCFs 
is because there were only two HCFs that referred samples 
for culture, insufficient to compute meaningful median. DST, 
drug sensitivity testing; HCFs, healthcare facilities.
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that is, referral for culture and DST for smear positive 
cases at 2 or 3 months of anti- TB treatment. We note that 
the algorithm for Xpert MTB/RIF has since changed to 
cover all presumptive TB cases and future studies should 
test whether this has improved the rate of utilisation.
Irrespective of the TB testing algorithm, our findings 
show that there are fundamental health system and 
socioeconomic—cultural barriers that hinder maximal 
uptake and utilisation of health technologies. In this 
paper, we focus on health system challenges and show 
that uptake and utilisation of molecular and microbi-
ological (culture) diagnostics in LMIC setting is still 
below expectation. Low uptake of diagnostics was mainly 
attributed to underfinancing of healthcare followed by 
lack of awareness by both district health officers and prac-
titioners at HCFs. Procurement difficulties, inadequate 
human resource and utilities such as water and electricity 
were highlighted as underlying suboptimal utilisation of 
molecular diagnostics hereby referred as Xpert MTB/
RIF and LPA.
While the private sector plays a major role in providing 
healthcare in the studied countries, government was 
found to be the main TB service provider, giving over 
80% of diagnostic and treatment services. This could be 
due to the complexity of managing TB that deters private 
healthcare providers from investing in it. In this case, 
the importance of government in expanding access of 
diagnosis and treatment services cannot be more empha-
sised. This makes public servants like district/county 
health officers even more important. Our findings show 
that the health officers were well informed of the state of 
health services in their areas of jurisdiction because their 
survey responses were corroborated by healthcare prac-
titioners at the HCFs. However, there was no correlation 
between the roles they performed and degree of imple-
mentation of diagnostic tools.
Despite its technical limitations, smear microscopy 
was widely implemented and utilised diagnostic for TB 
at all levels of the healthcare system in Kenya, Tanzania 
and Uganda.25 26 We believe low- acquisition cost, space 
and energy requirements make the microscope more 
attractive for HCFs to implement.27 Furthermore, the 
microscope is a multipurpose platform often serving 
other functions such as diagnosis of malaria, helminths 
and other bacterial infections in low- income coun-
tries. Technical limitations such as low sensitivity and 
specificity for diagnosing TB have less impact on the 
choice of diagnostic methodology. Technical challenges 
notwithstanding, for example, the low sensitivity of smear 
microscopy revealed by the 2016 Kenya TB prevalence 
survey where smear microscopy only detected 46% cases 
compared with 78% by Xpert MTB/RIF,28 a device that 
serves other diagnostic needs at the HCF makes more 
economic sense when deciding technologies to purchase. 
Therefore, investing in open rather than closed systems 
will go a long way in maximising uptake of new health 
technologies into policy and practice.
WHO approved Xpert MTB/RIF for implementation 
up to district hospital level.9 29 Our results show that, out 
of the 57 level 3 (district/subcounty) hospitals, only 56% 
had the Xpert MTB/RIF instruments and only 14% used 
the instruments to capacity, that is, performing eight or 
more tests per day. There was, instead, higher, close to 
100% coverage at level 4 and 5 HCFs with corresponding 
high full capacity utilisation of 27% and 51%, respec-
tively. It is, therefore, not clear the model followed in 
allocating the Xpert MTB/RIF instruments. For instance, 
in Kenya some counties had more than one Xpert MTB/
RIF instruments per subcounty while others had two 
Table 4 Human resource capacity at different HCF levels
Human resource capacity N (median (range))











Certificate holders 2 (0–2) 100% 83% 96% 65% 81%
Diploma holders 4 (0–18) 83% 100% 97% 91% 93%
Bachelor’s degree holders 2 (0–16) 0% 83% 57% 68% 93%
Master’s degree holders 0 (0–6) 0% 17% 0% 15% 38%
Medically qualified 5 (0–60) 100% 67% 83% 82% 74%
Clerical staff 1 (0–35) 17% 33% 63% 38% 57%
There is a trend to more highly qualified staff working in higher HCF levels.
HCF, healthcare facility.
Table 5 Qualities that inform choice of diagnostic test by 
practitioners
Diagnostic characteristic
No of participants 
who made the 
choice %
Expensive but more accurate 21 95
Cheap but less accurate 1 5
Longer time- to- result (2 weeks) 
but easy to perform
4 18
Shorter time- to- result (4 hours) 
but hard to perform
18 82
Accuracy and shorter time- to- result were considered more import 
than cost and ease of performing a test.
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instruments serving over 10 subcounties. In line with this 
observation Oliwa et al found variability in spatial distri-
bution of diagnostic services in Kenya suggesting a non- 
need driven allocation of diagnostic platforms.30
Only two (1.4%) of the audited HCFs used the Xpert 
MTB/RIF at point- of- care (in consultation room). In 
most cases, Xpert MTB/RIF results were not available 
in the same day, which means the speed advantage of 
Xpert MTB/RIF is not being realised. It is also not clear 
whether both doctor consultation and Xpert MTB/RIF 
testing were going on in the same room. The higher the 
HCF was in the health system hierarchy the higher the 
utilisation of Xpert MTB/RIF instruments. Limitations 
such as procurement, inadequacy of utilities and human 
resources were less frequent at higher level HCFs. In line 
with Pooran et al, our findings show that a hub system 
with an effective sample referral network may be more 
cost- effective than placing Xpert MTB/RIF machine at 
every HCF.31 With this approach, Xpert MTB/RIF may 
no longer qualify as near point- of- care test, but its utili-
sation will be more cost- effective. It has been suggested, 
however, that decentralisation of Xpert MTB/RIF can be 
cost- effective if the testing volumes are high in periph-
eral HCFs32 and there is good flow of funds to ensure 
availability of consumables. The high testing volume—
decentralisation model contradicts the novel battery 
powered single module point- of- care GeneXpert OMNI 
because it would require 16 hours to test eight samples 
thus increasing turn- around- time and cost more to imple-
ment in high TB burden settings.33 34
The LPA was the least implemented diagnostic test, 
yet it is the only approved rapid DST diagnostic for 
multidrug- resistant TB.35 Although approved for imple-
mentation at regional (L4) hospital, only 1/34 (3%) 
reported possession of LPA platform, which they were 
unfortunately unable to execute since they were trained 
by the test manufacturers. Lack of awareness emerged as 
the second main factor limiting the implementation of 
LPA. Surprisingly, almost 50% of health administrators 
and practitioners were not aware of LPA as a diagnostic 
for TB. Without awareness, there is no chance that such 
a diagnostic could be on the list of diagnostics to acquire 
by either HCF or district health administration. Further-
more, lack of awareness by practitioners is most likely 
to limit referrals for a given test and thus hindering its 
utilisation. Space intensiveness and laboriousness were 
highlighted as limitations for high utilisation by HCFs 
who had the LPA service. This is an eye opener for 
health technology developers to make technologies that 
are compatible with the available infrastructure as well 
as investing in increasing awareness and accessibility of 
these technologies especially in high TB burden settings.
Culture, the gold- standard diagnostic for TB36 was 
only found at a 5% implementation level across the 
three countries. All culture laboratories were associ-
ated with level 5 HCFs (national, consultant or zonal 
referral hospitals). On average culture laboratories 
serve 20 million or more people. Level 5 hospitals were 
more likely to perform culture and DST than lower 
HCFs which did not have the facilities. The presence 
of a culture laboratory at a facility did not change the 
time- to- culture- result, 2 months at level 3, 4 and 5 HCFs. 
An extended time- to- result could discourage clinicians 
from referring samples for culture since the results 
would not come in time to inform their clinical deci-
sions. The limited availability of culture labs and very 
low referrals for culture shows the three countries are 
not on course to achieve the universal DST access target 
of 100% by 2020 (WHO framework of indicators and 
targets). While culture is relatively easy to perform 
and cheaper, practitioners indicated they would spend 
a little more money for a hard to perform, expensive 
but accurate test with shorter time- to- result diagnostic 
technology. The underutilisation of culture could also 
be attributed to the WHO algorithm because the recom-
mendation at the time of the study suggested a culture 
be performed if the patient sputum is smear positive at 
month two or three of treatment.26 37
The low degree of coverage and utilisation of molec-
ular and culture tests revealed by our study is an indica-
tion that TB is most likely underdiagnosed in the region 
and more so, drug resistant TB. Global estimates show 
3 million TB cases go undetected every year.7 Our find-
ings also indicate that universal DST as recommended by 
WHO is currently unachievable until such a time when 
the countries have developed required diagnostic capa-
bilities.38 Treatment response monitoring needs of drug 
susceptible TB in the region are largely met due to wide 
coverage of smear microscopy but not drug resistant TB 
which requires a combination of microscopy and culture 
to monitor.37 39 Challenges associated with microscopy 
and culture for monitoring treatment response led the 
WHO to recognise the University of St Andrews devel-
oped TB Molecular Bacterial Load Assay (TB- MBLA) as 
a candidate to replace the two tests for monitoring TB 
treatment response.40 41 Like other molecular diagnostics, 
maximising uptake and utilisation of TB- MBLA requires 
addressing the barriers highlighted in this paper.
In the same trend, human resources capacity increased 
with the level of HCF, which partly explains higher 
uptake and utilisation of diagnostic services at these 
healthcare centres. Higher level HCFs are more likely to 
be in the urban centres with many social amenities attrac-
tive to professionals to come work and stay. Deliberate 
efforts must be made by national governments to ensure 
appointment and retention of healthcare practitioners in 
rural areas.
Health budgets in the study countries are largely donor 
dependent and thus any economic downturns in donor 
countries have ripple effect on the delivery of diagnostic 
and treatment services in LMIC settings. This is more so 
in the era of the COVID-19 pandemic that has ravaged 
global economy with traditional donor countries expe-
riencing up to 10% or more shrinking of their econo-
mies.12 It is more prudent to state that LMICs probably 
need to address the need to increase domestic funding 
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for healthcare including TB control services if the End 
TB Strategy has to be realised.
Engaging policy- makers unravelled valuable ideas on 
how to practically increase research impact and domestic 
financing to sustain uptake of health technologies and 
ensure quality healthcare. A Health tax on particular 
goods and services to build revenue base for funding 
healthcare programmes, research and innovation was 
recommended as the best way to go. The views from 
policy- makers clearly demonstrate how an invaluable 
partner they are in research and its translation to policy 
and practice. Response to COVID-19 is a good example 
where in most countries scientists and policy- makers 
have worked hand- in- hand to use available knowledge 
and tools to save lives while searching for more effective 
medical remedies goes on.
CONCLUSION
Our results have revealed that the health system set up 
favours maximal uptake and utilisation of both molecular 
and microbiological diagnostics at tertiary rather than 
lower healthcare levels. They point to a hub- centralised 
model of implementation as the most effective for 
maximising uptake and utilisation of molecular diagnos-
tics. It is important to note, however, that the success of 
a centralised system also requires unlocking the health 
system barriers to increase awareness, smoothen sample 
referral path and shorten results turn- around- time.42 
Centralised system may mean low access to diagnostic 
services by people in rural and hard to reach areas, thus 
innovative ways to ensure access by such communities are 
crucial. The findings also show low diagnostic capacity 
for drug resistant TB in the region, which means they are 
far from achieving the universal DST recommended by 
WHO. This paper further emphasises that health system 
bottlenecks are multifactorial and thus call for multisec-
toral interdisciplinary approach to address them.14
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